Table 6 Performance and outcome of SCT... | American Society of Hematology

Table 6

Performance and outcome of SCT after relapse

Evaluable	Total (n = 200)	B-lineage (n = 144)	T-lineage (n = 56)
Performance of SCT, n
Any SCT	149 (75%)	103 (72%)	46 (82%)
SCT in CR after 1st salvage	65 (32%)	51 (35%)	14 (25%)
SCT in later CR	21 (10%)	7 (5%)	14 (25%)
SCT without CR	63 (31%)	45 (31%)	18 (32%)
No SCT	51 (25%)	41 (28%)	10 (18%)
Outcome according to SCT*
Any SCT	38% ± 4%	36% ± 5%	43% ± 8%
SCT in CR after 1st salvage	56% ± 7%	50% ± 8%	77% ± 12%
SCT in later CR	39% ± 11%	51% ± 20%	34% ± 13%
SCT without CR	20% ± 5%	18% ± 6%	25% ± 11%
No SCT	0%†	0%†	0%†

Evaluable	Total (n = 200)	B-lineage (n = 144)	T-lineage (n = 56)
Performance of SCT, n
Any SCT	149 (75%)	103 (72%)	46 (82%)
SCT in CR after 1st salvage	65 (32%)	51 (35%)	14 (25%)
SCT in later CR	21 (10%)	7 (5%)	14 (25%)
SCT without CR	63 (31%)	45 (31%)	18 (32%)
No SCT	51 (25%)	41 (28%)	10 (18%)
Outcome according to SCT*
Any SCT	38% ± 4%	36% ± 5%	43% ± 8%
SCT in CR after 1st salvage	56% ± 7%	50% ± 8%	77% ± 12%
SCT in later CR	39% ± 11%	51% ± 20%	34% ± 13%
SCT without CR	20% ± 5%	18% ± 6%	25% ± 11%
No SCT	0%†	0%†	0%†

Patients with relapse during or after chemotherapy and without Ph⁺/BCR-ABL⁺ ALL or CNS involvement.

Survival rates are shown as the probability of survival ± SD at 3 years.

Survival at 1 year.